K. Lackey

发表

Comprehensive characterization of the Published Kinase Inhibitor Set

John P. Overington, D. J. Price, N. Sepetov, 2016, Nature Biotechnology.

Gene Family Targeted Molecular Design

K. Lackey, 2008 .

Gene Family Targeted Molecular Design: Lackey/Gene Family Targeted Molecular Design

K. Lackey, Karen E. Lackey, 2008 .

1 Medicinal Chemistry Approaches to Creating Targeted Medicines

K. Lackey, B. Roth, 2013 .

The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors.

K. Lackey, S. Dickerson, Jun Tang, 2013, Bioorganic & medicinal chemistry letters.

Drug Discoveries by Gene Family

K. Lackey, 2008 .

Synthesis of compounds designed to inhibit bacterial cell wall transglycosylation

K. Lackey, S. Hecker, Martha L. Minich, 1990 .

Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.

K. Lackey, 2006, Current topics in medicinal chemistry.

Potent dipeptide inhibitors of the pp60c-src SH2 domain.

P. Charifson, K. Lackey, L. Shewchuk, 1998, Journal of medicinal chemistry.

RET activation inhibits doxorubicin-induced apoptosis in SK-N-MC cells.

K. Lackey, M. Skinner, A. Freemerman, 2008, Anticancer research.

The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors.

K. Lackey, L. Shewchuk, M. Skinner, 2007, Bioorganic & medicinal chemistry letters.

Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I.

K. Lackey, D. Emerson, J. Besterman, 1995, Journal of medicinal chemistry.

Synthesis of 5-Substituted 7-Azaoxindoles via Palladium-catalyzed Reactions

K. Lackey, R. Hunter, M. Peel, 2001 .

The discovery of potent cRaf1 kinase inhibitors.

P. A. Harris, S. Frye, K. Lackey, 2000, Bioorganic & medicinal chemistry letters.

Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.

K. Lackey, Hideyuki Sato, S. Dickerson, 2008, Bioorganic & medicinal chemistry letters.

Reactions of a Cyclic Rhodium Carbenoid with Aromatic Compounds and Vinyl Ethers

M. Pirrung, K. Lackey, D. Sternbach, 1995 .

Synthesis of Substituted Quinoline-4-carboxylic Acids

K. Lackey, D. Sternbach, 1993 .

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Krystal J Alligood, Karen Lackey, K. Lackey, 2004, Cancer Research.

Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines.

K. Lackey, Laurie S. Kane-Carson, E. Wood, 2005, Bioorganic & medicinal chemistry letters.

Rigid analogs of camptothecin as DNA topoisomerase I inhibitors.

K. Lackey, D. Sternbach, J. Besterman, 1995, Journal of medicinal chemistry.

Synthesis of phenanthridin-3-one derivatives: Non-steroidal inhibitors of steroid 5-α-reductase

K. Lackey, R. Mook, C. Bennett, 1995 .

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.

K. Lackey, R. Mook, A. Walker, 2006, Bioorganic & medicinal chemistry letters.

Synthesis of Substituted Quinoline-4-carboxylic Acids.

K. Lackey, D. Sternbach, 2010 .

Synthesis of 2-chloro-5,7-dihydro-6 H -pyrrolo[2,3- d ]pyrimidin-6-one

P. A. Harris, K. Lackey, M. Cheung, 2001 .

Lapatinib, an Anticancer Kinase Inhibitor

K. Lackey, 2010 .

Medicinal Chemistry Approaches to Creating Targeted Medicines

Bruce D. Roth, Karen Lackey, K. Lackey, 2013 .

Comparison of the Biochemical and Kinetic Properties of the Type 1 Receptor Tyrosine Kinase Intracellular Domains

K. Lackey, K. Blackburn, S. Kadwell, 2002, The Journal of Biological Chemistry.

A public-private partnership to unlock the untargeted kinome.

Julian Blagg, Paul Workman, Bernhard Kuster, 2013, Nature chemical biology.

Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin.

K. Lackey, D. Emerson, D. Sternbach, 1996, Journal of medicinal chemistry.

Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles.

Karen Lackey, P. A. Harris, L. Kuyper, 2004, Bioorganic & medicinal chemistry letters.

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

K. Lackey, T. Gilmer, E. Wood, 2001, Molecular cancer therapeutics.

Reactions of a Cyclic Rhodium Carbenoid with Aromatic Compounds and Vinyl Ethers.

M. Pirrung, K. Lackey, D. Sternbach, 1995 .

Aza-stilbenes as potent and selective c-RAF inhibitors.

K. Lackey, R. Hunter, Ronda G. Davis-Ward, 2006, Bioorganic & medicinal chemistry letters.

Discovery and in vitro Evaluation of Potent TrkA Kinase Inhibitors: Oxindole and Aza‐Oxindoles.

L. Kuyper, K. Lackey, R. Hunter, 2004 .

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

K. Lackey, T. Gilmer, R. Crosby, 2001, Cancer research.

Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.

K. Lackey, T. Gilmer, R. Griffin, 2003, Bioorganic & medicinal chemistry letters.

Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors.

B G Benson, A M Hassell, P. A. Harris, 2001, Science.